Clinical Trial Update: APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST [Phase 1]

View source ↗

Summary

Phase 1 trial of APG-2449 as monotherapy or with pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer and advanced solid tumors …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• APG-2449
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor | Phase 1 | Status: RECRUITING